Amgen 2020 outlook falls short of Street estimates, shares down 3%

This post was originally published on this site

By Deena Beasley

(Reuters) – Amgen Inc (O:) on Thursday forecast 2020 earnings well short of current Wall Street estimates, sending shares of the largest U.S. biotechnology company down 3%.

For the full year, the company forecast earnings of $14.85 to $15.60 per share on revenue as high as $25.6 billion. Analysts had estimated 2020 adjusted earnings of $16.14 on revenue of $25.5 billion, according to Refinitiv IBES data.

A company official attributed the difference to lower interest income and Amgen’s recently acquired 20.5% stake in China’s BeiGene Ltd (HK:), which is not yet profitable.

For the fourth quarter of last year, Amgen said its sales fell 2% from a year earlier due to competition from lower-cost generic drugs and biosimilars, but share buybacks enabled the company to post a profit that topped Wall Street estimates.

Sales for the quarter totaled $5.88 billion. Total revenue fell 1% to $6.2 billion, which was ahead of the average analyst estimate of $6.06 billion.

Quarterly adjusted earnings per share rose 6% to $3.64, beating the average Wall Street estimate of $3.48.

Net earnings fell 5% to $2.85 per share due to higher operating costs partially offset by a lower share count.

Sales of older drugs such as white blood cell booster Neulasta and kidney drug Sensipar fell sharply due to competition from cheaper versions. Neulasta was down 43% at $665 million and Sensipar sales were off by 76% at $107 million.

Sales of newer drugs like cholesterol fighter Repatha and migraine drug Aimovig rose. Repatha was up by 26% to $200 million, while Aimovig rose 3% to $98 million in the quarter.

Amgen said it bought back around 6% of its outstanding shares last year.

Shares of the company were down $7.15, or 3.2%, at $219 in after hours trading.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Add Comment